Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Research and Markets - Renal Cluster Drug Development Pipeline Review 2017 - Key Companies are Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals & Vidasym | ||
| By: PR Newswire Association LLC. - 29 May 2017 | Back to overview list |
|
DUBLIN, May 29, 2017 /PRNewswire/ -- Research and Markets has announced the addition of the "Renal Cluster Drug Development Pipeline Review, 2017" report to their offering. This report provides an overview of the renal cluster pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Kidney Fibrosis, Chronic Kidney Disease (Chronic Renal Failure), Acute Renal Failure (ARF), Kidney Transplant Rejection, and also features dormant and discontinued projects. Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. There are a total of 39 products in development for this indication, by 28 companies and five academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Pharmaxis, Cellmid and Vascular Biogenics. Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. There are a total of 59 products in development for this indication, by 48 companies and two academic institutions. Key companies operating in this pipeline space include Angion Biomedica, Apceth Biopharma, AstraZeneca, Bayer, Evotec, Novartis, Sarfez Pharmaceuticals and Vidasym. While kidney transplant rejection treatments are largely focused on immune system molecular targets such as tumor necrosis factor alpha and complement factors, a range of cellular signaling components are being pursued in the other three key indications, including the activin receptors, cyclin dependent kinases, and growth factor receptors. Companies Mentioned
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/8gl35j/renal_cluster Media Contact: Research and Markets SOURCE Research and Markets 
|
||
|
||
 | Back to overview list | |